Day: May 29, 2025

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bakkt Holdings, Inc. (NYSE: BKKT) between March 25, 2024 and March 17, 2025, both dates inclusive (the “Class Period”), of the important June 2, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Bakkt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Bakkt class action, go to https://rosenlegal.com/submit-form/?case_id=5546 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) misrepresented the stability and/or diversity of its crypto services revenue; (2) failed to disclose Bakkt’s Crypto services revenue was substantially dependent on a single contract with Webull; (3) misrepresented its ability to maintain key client relationships; and (4) as a result of the foregoing, defendants’ positive statements about Bakkt’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bakkt class action, go to https://rosenlegal.com/submit-form/?case_id=5546 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9459497

Nyxoah to Present at the Jefferies Global Healthcare Conference

Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Tuesday, June 4, 2025, at 4:55pm ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1×1 meetings with institutional investors.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment

• ENGLISH_Nyxoah to Participate in the Jefferies Global Healthcare Conference_FINAL

GlobeNewswire Distribution ID 1001099538

gategroup Holding AG (“gategroup”) is pleased to announce the successful pricing of its comprehensive refinancing package, comprising two term loans of EUR 675 million and USD 500 million, both with a tenure of 7 years, and a CHF 300 million multicurrency revolving credit facility (the “new financing”) with a tenure of 6.5 years. The transaction was significantly oversubscribed and priced at the tighter end of guidance – strongly underscoring market confidence in gategroup’s strategy and performance.

This transaction represents gategroup’s debut as a Term Loan B (TLB) issuer, and the company is pleased to have attracted strong demand from leading global institutional investors. The level of interest received highlights the trust placed in gategroup’s credit profile, operational resilience, and future growth potential.

The New Financing is backed by a syndicate of top-tier global financial institutions and supports the refinancing of existing loans, notably the EUR 250 million Term Loan A and the CHF 415 million revolving credit facility, while also improving liquidity and flexibility.

“This successful refinancing marks a pivotal milestone for us,” said Christoph Schmitz, Chief Executive Officer of gategroup. “The broad-based support from a large group of premier banking partners and top global funds is a powerful endorsement of our business and strategy. This transaction diversifies gategroup´s funding base and allows us to invest in long-term initiatives, expand our global footprint, and further elevate our market-leading services in airline catering and hospitality.”

With the anticipated upgrade in its corporate credit rating to B2 (stable) / B+ (stable) by Moody’s and S&P Global respectively, gategroup gains improved access to capital markets. The refinancing significantly enhances the company’s capital structure and positions it for sustainable growth and value creation.

Urs Schwendinger, Chief Financial Officer of gategroup, added: “We are extremely pleased with the outcome of this transaction, which despite volatile market conditions has achieved several notable milestones among deals launched post-the US tariff announcements, including the largest cross-border loan issuance, largest debut issuance, and in its segment and rating universe, the largest new money loan deal and the largest Swiss issuance.”

For media and investor inquiries, please contact:

[email protected]

[email protected]

About gategroup

gategroup is the global leader in airline catering, retail-on-board, and hospitality products and services. Headquartered in Zurich, Switzerland, gategroup operates over 200 units in more than 60 countries, delivering culinary and retail excellence to passengers across all continents. Learn more at www.gategroup.com.

gategroup schließt Refinanzierung erfolgreich ab und ebnet den Weg für weiteres Wachstum und Marktexpansion

Die gategroup Holding AG („gategroup“) freut sich, den erfolgreichen Abschluss und die Preisfestsetzung ihres umfassenden Refinanzierungspakets bekannt zu geben. Die neue Finanzierung umfasst zwei Term Loan B Instrumente in Höhe von EUR 675 Mio. und USD 500 Mio., beide mit einer Laufzeit von 7 Jahren, und eine revolvierende Kreditfazilität in Höhe von CHF 300 Mio. mit einer Laufzeit von 6,5 Jahren (die „Neue Finanzierung“). Die Transaktion war deutlich überzeichnet und wurde zu attraktiven Konditionen abgeschlossen, was das Vertrauen der Märkte in gategroups Strategie und finanzielle Stärke unterstreicht.

Mit dieser Emission tritt gategroup erstmals als Term Loan B Emittentin auf, und das Unternehmen freut sich über die starke Nachfrage von führenden globalen institutionellen Investoren. Das große Interesse unterstreicht das Vertrauen in gategroups Marktposition, die operative Leistungsfähigkeit und das zukünftige Wachstumspotenzial.

Die Neue Finanzierung wird von einem Konsortium erstklassiger internationaler Finanzinstitute unterstützt und dient der Refinanzierung bestehender Kredite, insbesondere des EUR 250 Mio. Term Loan A und der existierenden revolvierenden Kreditfazilität in Höhe von CHF 415 Mio. Sie verbessert gleichzeitig die Liquidität und Flexibilität der Gruppe.

„Diese erfolgreiche Refinanzierung ist ein entscheidender Meilenstein für uns“, sagt Christoph Schmitz, Chief Executive Officer von gategroup. „Die breite Unterstützung durch eine große Gruppe führender Bankenpartner und globaler Top-Fonds sind ein starkes Signal für unser Geschäft, unsere Kunden und unsere Strategie. Die Transaktion schafft neue Optionen und ermöglicht es uns in langfristige Projekte zu investieren, unsere globale Präsenz auszubauen und unsere marktführenden Dienstleistungen im Bereich Airline-Catering und Hospitality weiter zu verbessern.“

Mit der erwarteten Verbesserung des Unternehmensratings auf B2 (stabil) / B+ (stabil) durch Moody’s bzw. S&P Global erhält gategroup einen verbesserten Zugang zu den internationalen Kapitalmärkten. Die Refinanzierung verbessert die Kapitalstruktur des Unternehmens erheblich und positioniert es für nachhaltiges Wachstum und Wertschöpfung.

Urs Schwendinger, Chief Financial Officer von gategroup, fügt hinzu: „Wir sind äußerst zufrieden mit dem Ergebnis dieser Transaktion, die trotz volatiler Marktbedingungen mehrere nennenswerte Merkmale unter den nach der Ankündigung der US-Zölle lancierten Finanztransaktionen aufweist, darunter die größte grenzüberschreitende Term Loan B Emission, die größte Emission einer „First Time“ Emittentin und in ihrem Segment und Rating-Universum die größte Neugelddarlehens-Transaktion“

Für Medien- und Investorenanfragen wenden Sie sich bitte an:

[email protected] 
[email protected]

Über gategroup 
gategroup ist der weltweit führende Anbieter von Airline-Catering, Retail-on-Board und Hospitality-Produkten und Dienstleistungen. Mit Hauptsitz in Zürich, Schweiz, betreibt gategroup über 200 Betriebe in mehr als 60 Ländern, die Passagieren auf allen Kontinenten kulinarische und einzelhandelsbezogene Spitzenleistungen bieten. Erfahren Sie mehr unter www.gategroup.com.

GlobeNewswire Distribution ID 1001099569

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital’s purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.

SO WHAT: If you sold and/or held Cerevel common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cerevel class action, go to https://rosenlegal.com/submit-form/?case_id=37997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements in connection with Cerevel’s October 16, 2023 secondary stock offering and in its January 18, 2024 proxy statement. As alleged in the complaint, the secondary stock offering was orchestrated by Cerevel’s controlling shareholders, Bain Capital, LP and Pfizer Inc., to allow Bain to increase its position in Cerevel at a deeply discounted price in advance of AbbVie Inc.’s undisclosed forthcoming acquisition of Cerevel. Just 51 days after the offering, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share – i.e., nearly double the offering price – and Bain’s discounted purchases from the offering resulted in it receiving a windfall of more than $120 million.

To join the Cerevel class action, go to https://rosenlegal.com/submit-form/?case_id=37997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID “9459496

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Treace Medical class action, go to https://rosenlegal.com/submit-form/?case_id=38284 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the “Lapiplasty”); (2) as a result, Treace Medical’s revenue declined and Treace Medical needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about Treace Medical’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Treace Medical class action, go to https://rosenlegal.com/submit-form/?case_id=38284 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9459474